Aoxing Pharmaceutical Company (AXN)
Aoxing Pharmaceutical Company Revenues: 1.807M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
AXN Revenues Rankings
| Overall | 3rd percentile | 4273 of 4425 |
| Sector | 15th percentile | 398 of 470 in Healthcare |
| Industry | 9th percentile | 18 of 20 in Drug Manufacturers - Major |
AXN Revenues Range, Past 5 Years
| Minimum | 0.8571M | Mar 2008 |
| Maximum | 3.964M | Jun 2008 |
| Average | 1.763M |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these AXN related companies
AXN News
$AXN filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3ydK
about 3 days ago by MarketBrief
about 3 days ago by MarketBrief
Aoxing Pharmaceutical Company Announces Third Quarter Fiscal 2012 Financial and Operational Results
May 15, 8:02PM Marketwire
May 15, 8:02PM Marketwire
Aoxing Pharmaceutical Company Appoints BDO China Dahua as Its Independent Auditor
Mar 22, 4:15PM Benzinga
Mar 22, 4:15PM Benzinga
Aoxing Pharmaceutical Company Announces Second Quarter Fiscal 2012 Financial and Operational Results
Feb 14, 5:00PM Marketwire
Feb 14, 5:00PM Marketwire
Aoxing Pharmaceutical Company Announces First Quarter Fiscal 2012 Financial and Operational Results
Nov 15, 8:15AM PR Newswire
Nov 15, 8:15AM PR Newswire
Aoxing Pharmaceutical Company Announces Special Funding From Hebei Province in China
Nov 03, 5:01PM Benzinga
Nov 03, 5:01PM Benzinga
Aoxing Pharmaceutical Company Announces Fiscal Year 2011 Financial and Operational Results
Sep 28, 11:18PM Marketwire
Sep 28, 11:18PM Marketwire
Aoxing Pharmaceutical Company to Present at Rodman & Renshaw Annual Global Investment Conference
Sep 08, 7:30AM PR Newswire
Sep 08, 7:30AM PR Newswire
Someone is playing with $AXN. Notice the wide daily swings. http://chart.ly/ywkmnlw
about 333 days ago by cougarhsv
about 333 days ago by cougarhsv
$AXN had 2 insider purchases last week. It's up from 0.94 to 1.56 , made it to $YHOO top movers list. #WatchInsiders
about 335 days ago by WatchInsiders
about 335 days ago by WatchInsiders
$AXN $1.11 Zhang Guoan officer (Senior VP of Finance) P 51,300 @ $0.96 amnt $49,259 proc'd $7,692 6/20/2011
about 342 days ago by canarionyc
about 342 days ago by canarionyc
$AXN $0.98 Zhang Guoan officer (Senior VP of Finance) P 47,000 @ $0.95 amnt $44,641 proc'd $1,410 6/17/2011
about 345 days ago by canarionyc
about 345 days ago by canarionyc
Aoxing Pharmaceutical Company Announces Issuance of Chinese Patent for Midazolam Maleate Oral Film
Jun 17, 2:08PM PR Newswire
Jun 17, 2:08PM PR Newswire
Aoxing Pharmaceutical Company Announces Details of Its 2011 Annual Meeting of Stockholders
Jun 13, 8:30AM PR Newswire
Jun 13, 8:30AM PR Newswire
Aoxing announces issuance of Chinese patent for Naloxone sublingual film
May 02, 10:15AM FlyOnTheWall
May 02, 10:15AM FlyOnTheWall
Aoxing Pharmaceutical Company Announces Issuance of Chinese Patent for Naloxone Sublingual Film
May 02, 9:00AM PR Newswire
May 02, 9:00AM PR Newswire
$AXN OSHEA JOHN P director B 7,205 @ $2.59 totl $18,660.90 1/19/2011 . 1st ins trans in Aoxing. #secfilings
about 493 days ago by canarionyc
about 493 days ago by canarionyc
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| AXN | 0.32 | -0.02 | -7.11% | 15.81M |
| AXL | 9.32 | -0.09 | -0.96% | 698.81M |
| AXK | 2.73 | -0.03 | -1.09% | 30.30M |
| AXJL | 57.50 | -0.53 | -0.91% | |
| AXFN | 20.75 | +0.00 | +0.00% | |
| AXE | 58.43 | -0.07 | -0.12% | 1.932B |
| AXDI | 56.32 | +0.00 | +0.00% | |
| AXAS | 2.56 | -0.07 | -2.66% | 236.19M |
| AWX | 3.47 | -0.06 | -1.70% | 11.07M |
| AWRE | 5.57 | -0.14 | -2.45% | 115.30M |
